Redwood City, CA – October 11, 2016 – SentreHEART Inc., an innovator of solutions for left atrial appendage closure (LAAC), announced today it has treated the first patients using the EclipseTM Surgical Device, which is approved and CE Marked in Europe. Krzysztof Bartus, M.D., PhD and Associate Professor of the Jagiellonian University, Department of Cardiovascular and Transplant Surgery in Krakow, Poland performed the procedures.
“The Eclipse™ Surgical Device, along with the LARIAT® Suture Delivery System, for LAA closure uniquely positions SentreHEART as the only company providing an option for both percutaneous and surgical closure of the left atrial appendage in Europe” said Russ Seiber, President and CEO of SentreHEART. “The Eclipse offers surgeons an intuitive and easy to use solution for immediate and complete LAA closure. We were pleased to have Dr. Bartus and his team involved in the first clinical use of the Eclipse.”
According to Dr. Bartus, “the procedures went exceedingly well. Complete closure was achieved in all cases. The ultra-low profile of the Eclipse improves visualization during placement, is easy to use and unlike other surgical solutions, does not require excessive grasping or manipulation of the left atrial appendage to close around its base.”
About Eclipse™ Surgical Left Atrial Appendage Closure Device
The Eclipse Surgical Left Atrial Appendage Closure Device is CE Marked for left atrial appendage closure under direct visualization. The Eclipse enables remote delivery of a 50mm pre-tied suture loop in a controlled and precise manner with immediate and complete LAA closure.
About SentreHEART, Inc.
SentreHEART is a privately owned medical device company based in Redwood City, CA. Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage. SentreHEART is the only company that offers both percutaneous and surgical options for immediate and complete LAA closure without the need for an implant.
# # #